Xu Ruilian, Director of Oncology Department of Shenzhen People’s Hospital, who recently visited the Nandu Health Lecture Hall, introduced that “surgery + chemotherapy + maintenance therapy” has become the standard treatment mode for ovarian cancer. Xu Ruilian said that the emergence of the PARP inhibitor niraparib has an epoch-making significance for the treatment of ovarian cancer, and it is effective for both BRCA-mutated and BRCA-unmutated patients. At present, the first-line population maintenance therapy of niraparib and the maintenance therapy of platinum-sensitive recurrent ovarian cancer have been included in the scope of medical insurance reimbursement in my country, and more ovarian cancer patients have the opportunity to receive maintenance therapy. [Reporter/Editor: Zeng Wenqiong Intern: Tang Jingyang]